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increased to 42.6% by 2005. In 2000, 89.5% of all AMI
patients was treated with thrombolysis as primary intervention,
7.8% underwent PCI, and 2.6% CABG; by 2005 these percent-
ages changed to 21.1%, 73.1%, and 5.8% respectively. We
compared the 30-day and one year mortality by intervention
groups. In 2005 without any intervention it was 27.5% vs
37.8% (30 days and 1 year), in the PCI group 6.1% vs 9.7%,
in the thrombolysis group 14.8% vs 18.7% and in the CABG
group 6.4% vs 12.3%. The 30-day mortality is independent of
gender but depends on age. The chance of 30-day survival
decreases due to diabetes and cancer (OR: 0.885 and 0.60,
respectively), shock (OR: 0.06) and resuscitation (OR: 0.07).
Survival is signiﬁcantly better in case of hypertension (OR: 1.4).
CONCLUSION: Administrative data proved to be appropriate
tools to develop quality indicators, thus its results can be very
useful in improving health care.
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OBJECTIVES: To quantify and qualify the risk of major bleed-
ing associated with the use of antibiotic drugs during coumarin
anticoagulant therapy in daily practice. METHODS: Data
for this retrospective cohort study were obtained from the
PHARMO Record Linkage System, including, among others,
linked drug-dispensing records and hospital records for over
three million individuals in deﬁned areas of The Netherlands.
The study cohort included all users of acenocoumarol or phen-
procoumon, aged 40–80 years, for the period 1996–2004. All
patients were followed until the end of their last coumarin dis-
pensing, hospitalisation for bleeding, death, or end of study
period. Number of days on coumarins alone, and number of
days on coumarins in combination with each antibiotic drug
during follow-up, were determined for each patient. We analy-
sed antibiotic drugs for which at least ﬁve patients experienced
a bleeding at least two weeks after anticoagulant therapy com-
menced, and which fell within the risk period of a single anti-
biotic drug. RESULTS: Respectively, 52,102 acenocoumarol
and 7,885 phenprocoumon users met the inclusion criteria for
the study cohort and contributed 139,159 patient-years of
follow-up. During follow-up 838 patients (1.4%) were hospit-
alised for bleeding while taking coumarins. The antibiotic drugs
for which at least ﬁve coumarin users had a bleeding were
doxycycline, amoxicillin, amoxicillin/clavulanic acid, ciprof-
loxacin and cotrimoxazole. Each of these antibiotic drugs was
associated with an increased risk of bleeding. Incidence rates
ranged from 5.2 major bleedings per 10,000 doxycycline-
dispensings to 11.2 major bleedings per 10,000 cotrimoxazole-
dispensings during coumarin use. Corresponding relative
risks for major bleeding, adjusted for gender and age, ranged
from 2.6 (95% CI 1.4–4.8) for doxycycline to 5.3 (95% CI
2.4–11.8) for cotrimoxazole. CONCLUSION: Doxycycline,
amoxicillin, amoxicillin/clavulanic acid, ciproﬂoxacin and cot-
rimoxazole are the main antibiotic drugs associated with an
increased risk of major bleeding during coumarin anticoagulant
therapy in daily practice.
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OBJECTIVES: To characterize epidemiological risk factors,
review clinical outcomes, and overall costs associated with treat-
ing bleeding related to cardiac surgery, and identify areas for
further research. METHODS: A systematic literature search was
performed (1996-March 2007) using terms designed to identify
publications describing epidemiology and associated risk factors,
clinical outcomes, and economic impact of bleeding in cardiac
surgery patients. Studies were identiﬁed through electronic Med-
line® and PubMed® searches. Manual review of bibliographies
within these papers allowed identiﬁcation of additional articles.
RESULTS: A total of 36 (epidemiology: n = 13, clinical out-
comes: n = 14, and economic burden: n = 9) papers [manual
search: n = 12] were included for review. Incidence of bleeding
associated with major cardiac surgical procedures varied widely,
ranging from 0.4%–19.0%, partly attributable to the types of
cardiac operations as well as to differences in the deﬁnition of
bleeding. Pre-operative smaller body mass index, use of anti-
thrombotic drugs, nonelective surgery, increased age, and redo
procedures were associated with bleeding, while embolic events
were found to be major complications. Costs associated with
bleeding requiring transfusion ranged from $397 (blood prod-
ucts only) to $10,225 per patient (all treatment costs), with
hospital LOS as the major cost contributor. Mean cost of open-
heart surgeries [including coronary artery bypass graft (CABG)
and valve replacements] range from $25,057 to $79,795, with
patients undergoing CABG found to have an incremental cost of
$3,866 associated with bleeding. Primary pharmacological treat-
ments for bleeding among cardiac surgery patients included anti-
ﬁbrinolytics and procoagulants. CONCLUSION: Post-operative
bleeding remains a central clinical outcome in cardiac surgery
with signiﬁcant economic impact despite improvements in peri-
operative bleeding management. Sufﬁcient information on recent
cost estimates as well as differences in bleeding costs associated
with various cardiac procedures is lacking. Further research
investigating the economic consequences of bleeding associated
with cardiac surgery is warranted.
CARDIOVASCULAR DISEASE—Cost Studies
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OBJECTIVES: Introduction. The polish system of medication
reimbursement is based on positive list. The government decides
which medication could be reimbursed by adding or removing it
from the list. Additional tool for reimbursement control is the
“medication refund limit” (MRL). The same MRL per DDD is
set for each INN separately or for group of medication, which
have the same indication, form and dose. The payer (National
Fund of Health) partially refunds the cost of medication below
the MRL. The difference between the MRL and price is paid by
patient. In 2006 the government changed the MRL and ofﬁcial
prices for some medication. The aim is to assess the impact of
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